Drugs / Ficerafusp alfa
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04429542 | Jun 2020 → Oct 2027 expected | anal canal squamous cell carcinoma, head and neck squamous cell carcinoma, malignant epithelial tumor of ovary, malignant pancreatic neoplasm +2 | Bicara Therapeutics | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07552558 | Jun 2026 → Aug 2028 expected | head and neck squamous cell carcinoma | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07807163 | Sep 2026 → Mar 2028 expected | head and neck squamous cell carcinoma | Bicara Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT07465276 | Mar 2026 → Apr 2028 expected | head and neck squamous cell carcinoma | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT07529873 | Mar 2026 → Apr 2030 expected | head and neck squamous cell carcinoma | Groupe Oncologie Radiotherapie Tete et Cou | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06788990 | Jan 2025 → Apr 2028 expected | head and neck squamous cell carcinoma | Bicara Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ficerafusp alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07552558 ↗ |
| Known as | BCA 101 | “A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC” NCT07807163 ↗3“FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo” NCT06788990 ↗ “Ficerafusp alfa (BCA 101)” NCT07529873 ↗ |
| Known as | FmAb2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095314 ↗ |
| Modality | Monoclonal antibody | “EGFR/TGFβ fusion monoclonal antibody” NCT04429542 ↗ |
| Route | Intravenous | “Route: IV Infusion” NCT04429542 ↗ |
| Target | EGFR | “targets both EGFR with TGFβ” NCT04429542 ↗ |